Literature DB >> 27956623

Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5.

Fotini Vogiatzi1, Dominique T Brandt2, Jean Schneikert1, Jeannette Fuchs1, Katharina Grikscheit2, Michael Wanzel1, Evangelos Pavlakis1, Joël P Charles1, Oleg Timofeev1, Andrea Nist3, Marco Mernberger1,3, Eva J Kantelhardt4, Udo Siebolts5, Frank Bartel5, Ralf Jacob6, Ariane Rath7, Roland Moll7, Robert Grosse2, Thorsten Stiewe8,3,9.   

Abstract

Mutations in the p53 tumor suppressor gene are the most frequent genetic alteration in cancer and are often associated with progression from benign to invasive stages with metastatic potential. Mutations inactivate tumor suppression by p53, and some endow the protein with novel gain of function (GOF) properties that actively promote tumor progression and metastasis. By comparative gene expression profiling of p53-mutated and p53-depleted cancer cells, we identified ectonucleoside triphosphate diphosphohydrolase 5 (ENTPD5) as a mutant p53 target gene, which functions as a uridine 5'-diphosphatase (UDPase) in the endoplasmic reticulum (ER) to promote the folding of N-glycosylated membrane proteins. A comprehensive pan-cancer analysis revealed a highly significant correlation between p53 GOF mutations and ENTPD5 expression. Mechanistically, mutp53 is recruited by Sp1 to the ENTPD5 core promoter to induce its expression. We show ENTPD5 to be a mediator of mutant p53 GOF activity in clonogenic growth, architectural tissue remodeling, migration, invasion, and lung colonization in an experimental metastasis mouse model. Our study reveals folding of N-glycosylated membrane proteins in the ER as a mechanism underlying the metastatic progression of tumors with mutp53 that could provide new possibilities for cancer treatment.

Entities:  

Keywords:  ENTPD5; N-glycosylation; metastasis; p53; tumor suppressor

Mesh:

Substances:

Year:  2016        PMID: 27956623      PMCID: PMC5206569          DOI: 10.1073/pnas.1612711114

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  50 in total

1.  The ER UDPase ENTPD5 promotes protein N-glycosylation, the Warburg effect, and proliferation in the PTEN pathway.

Authors:  Min Fang; Zhirong Shen; Song Huang; Liping Zhao; She Chen; Tak W Mak; Xiaodong Wang
Journal:  Cell       Date:  2010-11-11       Impact factor: 41.582

Review 2.  Translating p53 into the clinic.

Authors:  Chit Fang Cheok; Chandra S Verma; José Baselga; David P Lane
Journal:  Nat Rev Clin Oncol       Date:  2010-10-26       Impact factor: 66.675

3.  A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain.

Authors:  C Gaiddon; M Lokshin; J Ahn; T Zhang; C Prives
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

4.  A Pin1/mutant p53 axis promotes aggressiveness in breast cancer.

Authors:  Javier E Girardini; Marco Napoli; Silvano Piazza; Alessandra Rustighi; Carolina Marotta; Enrico Radaelli; Valeria Capaci; Lee Jordan; Phil Quinlan; Alastair Thompson; Miguel Mano; Antonio Rosato; Tim Crook; Eugenio Scanziani; Anthony R Means; Guillermina Lozano; Claudio Schneider; Giannino Del Sal
Journal:  Cancer Cell       Date:  2011-07-12       Impact factor: 31.743

5.  Cell-type, dose, and mutation-type specificity dictate mutant p53 functions in vivo.

Authors:  Ming Kei Lee; Wei Wei Teoh; Beng Hooi Phang; Wei Min Tong; Zhao Qi Wang; Kanaga Sabapathy
Journal:  Cancer Cell       Date:  2012-12-11       Impact factor: 31.743

Review 6.  Mutant p53 gain-of-function in cancer.

Authors:  Moshe Oren; Varda Rotter
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-02       Impact factor: 10.005

Review 7.  Roles of N-linked glycans in the endoplasmic reticulum.

Authors:  Ari Helenius; Markus Aebi
Journal:  Annu Rev Biochem       Date:  2004       Impact factor: 23.643

8.  Mutant p53 drives invasion by promoting integrin recycling.

Authors:  Patricia A J Muller; Patrick T Caswell; Brendan Doyle; Marcin P Iwanicki; Ee H Tan; Saadia Karim; Natalia Lukashchuk; David A Gillespie; Robert L Ludwig; Pauline Gosselin; Anne Cromer; Joan S Brugge; Owen J Sansom; Jim C Norman; Karen H Vousden
Journal:  Cell       Date:  2009-12-24       Impact factor: 41.582

9.  Ethidium bromide provides a simple tool for identifying genuine DNA-independent protein associations.

Authors:  J S Lai; W Herr
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

10.  Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion.

Authors:  P A J Muller; A G Trinidad; P Timpson; J P Morton; S Zanivan; P V E van den Berghe; C Nixon; S A Karim; P T Caswell; J E Noll; C R Coffill; D P Lane; O J Sansom; P M Neilsen; J C Norman; K H Vousden
Journal:  Oncogene       Date:  2012-05-14       Impact factor: 9.867

View more
  41 in total

1.  p53 gain-of-function mutations promote metastasis via ENTPD5 upregulation and enhanced N-glycoprotein folding.

Authors:  Oleg Timofeev; Thorsten Stiewe
Journal:  Mol Cell Oncol       Date:  2017-02-03

Review 2.  Context is everything: extrinsic signalling and gain-of-function p53 mutants.

Authors:  Ivano Amelio; Gerry Melino
Journal:  Cell Death Discov       Date:  2020-03-23

3.  Pro-metastatic p53 mutants control folding of N-glycoproteins.

Authors:  Jean Schneikert; Thorsten Stiewe
Journal:  Cell Cycle       Date:  2017-02-06       Impact factor: 4.534

4.  Development of a Fully Cross-Validated Bayesian Network Approach for Local Control Prediction in Lung Cancer.

Authors:  Yi Luo; Daniel McShan; Dipankar Ray; Martha Matuszak; Shruti Jolly; Theodore Lawrence; Feng Ming Kong; Randall Ten Haken; Issam El Naqa
Journal:  IEEE Trans Radiat Plasma Med Sci       Date:  2018-05-02

Review 5.  Mutant p53 on the Path to Metastasis.

Authors:  Qiaosi Tang; Zhenyi Su; Wei Gu; Anil K Rustgi
Journal:  Trends Cancer       Date:  2019-12-16

6.  The Chk2-PKM2 axis promotes metabolic control of vasculogenic mimicry formation in p53-mutated triple-negative breast cancer.

Authors:  Pei Yu; Xiong Zhu; Jia-Le Zhu; Yu-Bao Han; Hao Zhang; Xiang Zhou; Lei Yang; Yuan-Zheng Xia; Chao Zhang; Ling-Yi Kong
Journal:  Oncogene       Date:  2021-07-09       Impact factor: 9.867

7.  [ENTPD5 gene is highly expressed in epithelial ovarian cancer: analysis based on Oncomine database and bioinformatics].

Authors:  H Wang; X Chen; Y Chen; Y Cao; Y Chen; G Liu; L Huang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-04-20

Review 8.  ENTPD5 splice variants: novel players in cancer?

Authors:  Francesca Arruga
Journal:  Purinergic Signal       Date:  2021-07-17       Impact factor: 3.765

9.  ENTPD5: identification of splicing variants and their impact on cancer survival.

Authors:  Rafael Paschoal de Campos; Marcia Rosângela Wink; Guido Lenz
Journal:  Purinergic Signal       Date:  2021-06-02       Impact factor: 3.765

10.  ST6GalNAc-I promotes lung cancer metastasis by altering MUC5AC sialylation.

Authors:  Imayavaramban Lakshmanan; Sanjib Chaudhary; Raghupathy Vengoji; Parthasarathy Seshacharyulu; Satyanarayana Rachagani; Joseph Carmicheal; Rahat Jahan; Pranita Atri; Ramakanth Chirravuri-Venkata; Rohitesh Gupta; Saravanakumar Marimuthu; Naveenkumar Perumal; Sanchita Rauth; Sukhwinder Kaur; Kavita Mallya; Lynette M Smith; Subodh M Lele; Moorthy P Ponnusamy; Mohd W Nasser; Ravi Salgia; Surinder K Batra; Apar Kishor Ganti
Journal:  Mol Oncol       Date:  2021-05-01       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.